Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Oncology
Ophthalmology
Respiratory
Sandoz Biopharmaceuticals
Global Health
Abbreviations
Tafinlar® - BRAF inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
Target Patients
Read-out Milesstone(s)
Publication
NCT01677741 (CDRB436A2102)
BRAFV600 mutant cancers
Phase 1/2
85
Safety, tolerability and pharmacokinetics
Single-arm study of oral dabrafenib (dose based on age and weight)
Pediatric subjects aged 1 year to <18 years with advanced BRAF V600-mutation
positive solid tumors
H1-2021 (actual)
Kieran MW et al. Clin Cancer Res 2019;25(24):7294-7302 (PK analysis)
Hargrave DR et al. Clin Cancer Res 2019;25(24):7303-7311 (safety/efficacy in low-
grade gliomas)
115 Investor Relations | Q2 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation